William Blair downgraded Charles River (CRL) to Market Perform from Outperform without a price target “There is simply too much working against Charles River in the near term to make the stock interesting,” the analyst tells investors in a research note. The firm is concerned about the near-term outlook for Charles, saying that given the “looming headwind” from loss of exclusivity, large pharma will continue to prioritize products closer to approval that have the potential to contribute revenue in the near term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River downgraded to Market Perform from Outperform at William Blair
- Salesforce upgraded, Southwest downgraded: Wall Street’s top analyst calls
- Charles River downgraded to Neutral from Buy at UBS
- Charles River and Akron Bio team on CSS integration for cell therapy
- Charles River Labs Discusses 2025 Financial Outlook